1176327-06-2

Upstream product

• 1176327-05-1 [3-bromo-5-(2-methoxyethoxy)benzyl](triphenyl)phosphonium bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1176327-04-0 1-bromo-3-(bromomethyl)-5-(2-methoxyethoxy)benzene 
• 1176327-02-8 [3-bromo-5-(2-methoxyethoxy)phenyl]methanol 
• 1160184-91-7 3-bromo-5-(2-methoxyethoxy)benzaldehyde 
• 1160184-89-3 1,3-dibromo-5-(2-methoxyethoxy)benzene 
• 1176327-03-9 3-Bromo-5-(2-methoxyethoxy)benzyl methanesulfonate 
• 626-41-5 3,5-dibromophenol 

Downstream Products

• 1176327-07-3 tert-butyl 4-[3-bromo-5-(2-methoxyethoxy)benzyl]piperidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT1A receptor agonistic activity

We have previously shown that SMP-304, a serotonin uptake inhibitor with weak 5-HT1A partial agonistic activity, may act under high serotonin levels as a 5-HT1A antagonist that improves the onset of paroxetine in the rat swimming test. However, SMP-304 is mostly metabolized by CYP2D6, indicating limited efficacy among individuals and increased side effects. To reduce CYP2D6 metabolic contribution and enhance SERT/5-HT1A binding affinity, we carried out a series of substitutions at the bromine atom in the left part of the benzene ring of SMP-304 and replaced the right part of SMP-304 with a chroman-4-one. This optimization work led to the identification of the antidepressant candidate DSP-1053 as a potent SERT inhibitor with partial 5-HT1A receptor agonistic activity. DSP-1053 showed low CYP2D6 metabolic contribution and a robust increase in serotonin levels in the rat frontal cortex.

BENZYLPIPERIZINE COMPOUND

Disclosed is a benzylpiperizine compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a medicinal agent such as an antidepressant agent. (In the formula (1), R1 represents a hydrogen atom or a met